Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management

Li, Liu-Cheng; Han, Yong-Yue; Zhang, Zhihui; Zhou, Wencheng; Fang, Hua; Qu, Jiao; Kan, Lian‐Di

doi:10.2147/dddt.s286315

Cited by 11 publications

(10 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no effective way to reverse the decline of lung function; the only way to reduce the frequency and severity of acute exacerbations of COPD is to relieve the symptoms and thereby improve the quality of life of COPD patients. Current approaches focus mainly on symptomatic treatment [6]. The two clinical phenotypes of COPD are emphysema and bronchiolitis [7].…”

Section: Ivyspringmentioning

confidence: 99%

Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a

Wu¹,

Ma²,

Zhang³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) affects the health of more than 300 million people worldwide; at present, there is no effective drug to treat COPD. Smoking is the most important risk factor, but the molecular mechanism by which smoking causes the disease is unclear. The senescence of lung epithelial cells is related to development of COPD. Regulation of miRNAs is the main epigenetic mechanism related to aging. β-Galactose staining showed that the lung tissues of smokers have a higher degree of cellular senescence, and the expression of miR-125a-5p is high. This effect is obvious for smokers with COPD/emphysema, and there is a negative correlation between miR-125a-5p levels and values for forced expiratory volume in one second (FEV1)/forced vital capacity (FVC). After Balb/c mice were chronically exposed to various concentrations of cigarette smoke (CS), plethysmography showed that lung function was impaired, lung tissue senescence was increased, and the senescence-associated secretory phenotype (SASP) in bronchoalveolar lavage fluid was increased. For mouse lung epithelial (MLE)-12 cells treated with cigarette smoke extract (CSE), Sp1 and SIRT1 levels were low, HIF-1α acetylation levels were high, and cell senescence and secretion of SASP factors were elevated. Down-regulation of miR-125a-5p or up-regulation of Sp1 reversed these effects. In addition, compared with mice exposed to CS, knockdown of miR-125a-5p reduced lung epithelial cell senescence and COPD/emphysema. Therefore, in smoking-induced COPD, elevated miR-125a-5p participates in the senescence of lung epithelial cells through Sp1/SIRT1/HIF-1α. These findings provide evidence related to the pathogenesis of COPD/emphysema caused by chronic smoking.

show abstract

Section: Ivyspringmentioning

confidence: 99%

Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a

Wu¹,

Ma²,

Zhang³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…These immunostimulatory effects collectively work together for killing pathogens entering the lungs and thereby prevent infection in the respiratory tract ( 88 , 89 ). Existing indications of this vaccine include COVID-19 [Clinical Trials Identifier number NCT04312997 and NCT04313023], stem cell transplant [Clinical Trials Identifier number NCT03097796], and chronic obstructive pulmonary diseases [Clinical Trials Identifier number NCT03794557] ( 79 , 88 , 91 , 92 ).…”

Section: Unapproved Vaccinesmentioning

confidence: 99%

A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines

Banerjee¹,

Banerjee²,

Singh³

et al. 2022

AAPS PharmSciTech

View full text Add to dashboard Cite

“…Improving medication compliance of patients has become a great challenge for doctors, pharmacists, nurses and other medical personnel (L. C. Li, Han, et al, 2021). For the eradication of H. pylori, patient medication compliance was reported as an independent effecting factor (Lan et al, 2022;Shawky et al, 2022).…”

Section: Medication Compliance In H Pylori Treatment Managementmentioning

confidence: 99%

“…The factors reported affecting medication compliance were unwanted drug effects, changes in drug regimens, and refilling the prescriptions after they ran out (Zairina et al, 2022). Improving medication compliance of patients has become a great challenge for doctors, pharmacists, nurses and other medical personnel (L. C. Li, Han, et al, 2021). For the eradication of H. pylori , patient medication compliance was reported as an independent effecting factor (Lan et al, 2022; Shawky et al, 2022).…”

Section: Two Major Challenges In H Pylori Treatment Managementmentioning

confidence: 99%

Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection

Wang

Chen

Pei

et al. 2022

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Half of the world's population is Helicobacter pylori carrier. Updated guidelines and consensus have been issued across regions with the main aim of reducing social transmission and increasing H. pylori eradication rate. Although alternative therapies including traditional Chinese medicine and probiotics have also been used to improve H. pylori eradication rate in clinical practice, current mainstream treatment is still dependent on triple and quadruple therapies that includes antibacterial agents (e.g., amoxicillin and furazolidone) and proton pump inhibitor. Researches also assessed the eradication rate of optimized high-dose dual therapy in treating H. pylori infection. With the increase of antibiotic resistance rate, the treatment strategies for H. pylori infection are constantly adjusted and improved. Besides, low medication compliance is another key influencing factor for H. pylori treatment failure. Emerging studies indicate that pharmacists' intervention and new pharmaceutical care methods can enhance patient medication compliance, reduce adverse drug reactions, and improve H. pylori eradication rate. The purpose of this review is to summarize the advances in treating H. pylori infection and highlight the necessity of developing novel strategies to cope with the increasing challenges and to achieve personalized medication. Also, this review attaches great importance to pharmacists in optimizing H. pylori treatment outcomes as a routine part of therapy.

show abstract

Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management

Cited by 11 publications

References 77 publications

Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a

Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a

A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines

Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection

Contact Info

Product

Resources

About